At RSNA 2025, Niccolo Stefani, Business Leader Population Health & Clinical AI at Deep Health, discusses how the company’s population health portfolio is driving earlier disease detection, improving diagnostic processes, and preparing for a major European expansion in 2026.
A central point of Stefani’s discussion is Deep Health’s effort to shift diagnosis toward earlier disease stages. The company reports significant progress in cancer screening programmes, noting 76% detection of stage I and II cancers in the UK. Earlier identification is closely tied to improving diagnostic operations, lowering the cost of diagnosis, and extending access to a wider patient population.
The direction reflects broader trends in healthcare systems aiming to balance efficiency with equitable access. By focusing on operational improvements and cost reduction, Deep Health seeks to enable earlier diagnosis at scale and support more consistent outcomes across diverse clinical environments.
Looking to 2026, Stefani highlights the company’s plans to introduce an expanded portfolio to the European market. Upcoming additions include brain age and brain health assessment solutions, alongside updated prostate and lung screening tools. Together, these developments demonstrate Deep Health’s continued focus on advancing population health through earlier detection and broader diagnostic capability.
